Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate

Patent Citations (88)

Non-Patent Literature (69)

• Ogitani et al Clin. Cancer Res. vol. 22 p. 5097 (Mar. 2016). (Year: 2016).Examiner
• NCT02564900, 13 pages (Year: 2015).Examiner
• Carceller Drugs of Today vol. 51(11) p. 669 (Nov. 2015), (Year: 2015).Examiner
• Russian Office Action dated Mar. 5, 2019 in corresponding application No. 2016143351.Applicant
• Sievers et al, Antibody-Drug Conjugates in Cancer Therapy, Annual Review of Medicine, 2013, vol. 64, No. 1, pp. 15-29.Applicant
• United States Office Action dated Apr. 5, 2019 in U.S. Appl. No. 15/821,697.Applicant
• International Searching Authority, “International Search Report,” issued in connection with International Patent Application No. PCT/JP2017/036215, dated Nov. 21, 2017.Applicant
• International Searching Authority, “Written Opinion,” issued in connection with International Patent Application No. PCT/JP2017/036215, dated Nov. 21, 2017.Applicant
• Adams et al., “Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab,” Cancer Immunol. Immunother., vol. 55, 2006, pp. 717-727.Applicant
• Alley et al., “Antibody-drug conjugates: targeted drug delivery for cancer,” Current Opinion in Chemical Biology, vol. 14, 2010, pp. 529-537.Applicant
• Barginear et al., “Trastuzumab-DM1: A Review of the Novel Immuno-Conjugate for HER2-Overexpressing Breast Cancer,” The Open Breast Cancer Journal, vol. 1, 2009, pp. 25-30.Applicant
• Barok et al., “Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer,” Cancer Letters, vol. 306, 2011, pp. 172-179.Applicant
• Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer,” Journal of Clinical Oncology, vol. 14, No. 3, Mar. 1996, pp. 737-744.Applicant
• Beck, Alain, “The Next Generation of Antibody-drug Conjugates Comes of Age,” Discovery Medicine, vol. 10, No. 53, Oct. 16, 2010 (8 pages).Applicant
• Behrens et al., “Methods for site-specific drug conjugation to antibodies,” mAbs, vol. 6, No. 1, 2014, pp. 46-53.Applicant
• Burke et al., “Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues”, Bioconjugate Chemistry, vol. 20, No. 6, 2009, pp. 1242-1250.Applicant
• Burris, III et al., “Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy,” Journal of Clinical Oncology, vol. 29, No. 4, Feb. 1, 2011, pp. 398-405.Applicant
• Cardillo et al., “Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys,” Clinical Cancer Research, vol. 17, No. 10, Mar. 3, 2011, pp. 3157-3169.Applicant
• Coussens et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene,” Science, vol. 230, Dec. 1985, pp. 1132-1139.Applicant
• Damle, Nitin K., “Tumour-targeted chemotherapy with immunoconjugates of calicheamicin,” Expert Opinion Biol. Ther., vol. 4, No. 9, 2004, pp. 1445-1452.Applicant
• De Jager et al., “DX-8951f: Summary of Phase I Clinical Trials,” Ann. N.Y. Acad. Sci., vol. 922, 2000, pp. 260-273.Applicant
• Di Fiore et al., “erbB-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells,” Science, vol. 237, Jul. 1987, pp. 178-182.Applicant
• Ducry et al., “Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjugate Chem., vol. 21, No. 1, 2010, pp. 5-13.Applicant
• Esteva et al., “A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for 5 Days Every 3 Weeks to Patients with Metastatic Breast Carcinoma,” American Cancer Society, 2003, 900-907.Applicant
• Fendly et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product,” Cancer Research, vol. 50, Mar. 1, 1990, pp. 1550-1558.Applicant
• Fukushige et al., “Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell Line,” Molecular and Cellular Biology, vol. 6, No. 3, Mar. 1986, pp. 955-958.Applicant
• Graus-Porta et al., “ERbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling,” The EMBO Journal, vol. 16, No. 7, 1997, pp. 1647-1655.Applicant
• Gravalos et al., “HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target,” Annals of Oncology, vol. 19, 2008, pp. 1523-1529.Applicant
• Hardwick et al., “Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis,” European Journal of Surgical Oncology, vol. 23, 1997, pp. 30-35.Applicant
• Hudis, M.D., Clifford A., “Trastuzumab—Mechanism of Action and Use in Clinical Practice,” The New England Journal of Medicine, vol. 357, No. 1, 2007, pp. 39-51.Applicant
• Hudziak et al., “Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells,” Proc. Natl. Acad. Sci. USA, vol. 84, Oct. 1987, pp. 7159-7163.Applicant
• Inoue et al., “CM-Dextran-Polyalcohol-Camptothecin Conjugate: DE-310 with a Novel Carrier System and Its Preclinical Data,” Polymer Drugs in the Clinical Stage, 2003, pp. 145-153.Applicant
• Joto et al., “DX-8951F, A Water-Soluble Camptothecin Analog, Exhibits Potent Antitumor Activity Against a Human Lung Cancer Cell Line and its SN-38-Resistant Variant,” Int. J. Cancer, vol. 72, 1997, pp. 680-686.Applicant
• Kaptain et al., “Her-2/neu and Breast Cancer,” Diagnostic Molecular Pathology, vol. 10, No. 3, 2001, pp. 139-152.Applicant
• Karunagaran et al., “ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer,” The EMBO Journal, vol. 15, No. 2, 1996, pp. 254-264.Applicant
• Korkaya et al., “HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion,” Oncogene, vol. 27, 2008, pp. 6120-6130.Applicant
• Kumazawa et al., “Antitumor activity of DX-8951f: a new camptothecin derivative,” Expert Opinion Invest. Drugs vol. 7, No. 4, 1998, pp. 625-632.Applicant
• Kumazawa et al., “DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: Potent antitumor activities in various murine tumor models,” Cancer Sci., vol. 95, No. 2, Feb. 2004, pp. 168-175.Applicant
• Kumazawa et al., “Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice,” Cancer Chemother. Pharmacol., vol. 42, 1998, pp. 210-220.Applicant
• Loganzo et al., “Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments,” Molecular Cancer Therapeutics, vol. 14, No. 4, Apr. 2015, pp. 952-963.Applicant
• Masubuchi, N., “Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice,” Pharmazie, vol. 59, No. 5, 2004, pp. 374-377.Applicant
• Mitsui et al., “A New Water-soluble Camptothecin Derivative, DX-8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo,” Jpn. J. Cancer Res, vol. 86, Aug. 1995, pp. 776-782.Applicant
• Nakada et al., “Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads,” Bioorganic & Medicinal Chemistry Letters, vol. 26, 2016, pp. 1542-1545.Applicant
• Ochi et al., “A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951,” Cancer Chemother Pharmacol, vol. 55, 2005, pp. 323-332.Applicant
• Ogitani et al., “DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1,” Clinical Cancer Research, vol. 22, No. 20, Oct. 15, 2016, pp. 5097-5108.Applicant
• Oguma et al., “Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry,” Biomedical Chromatography, vol. 19, 2005, pp. 19-26.Applicant
• Senter et al., “The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma,” Nature Biotechnology, vol. 30, No. 7, Jul. 2012, pp. 631-637.Applicant
• Shen et al., “Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates,” Nature Biotechnology, vol. 30, Jan. 22, 2012, pp. 184-189.Applicant
• Shiose et al., “Systematic Research of Peptide Spacers Controlling Drug Release from Macromolecular Prodrug System, Carboxymethyldextran Polyalcohol-Peptide-Drug Conjugates,” Bioconjugate Chem., vol. 20, 2009, pp. 60-70.Applicant
• Slamon et al., “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene,” Science, vol. 235, Jan. 9, 1987, pp. 177-182.Applicant
• Slamon et al., “Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer,” Science, vol. 244, May 12, 1989, pp. 707-712.Applicant
• Sliwkowski et al., “Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin.” The Journal of Biological Chemistry, vol. 269, No. 20, 1994, pp. 14661-14665.Applicant
• Sliwkowski et al., “Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptin),” Seminars in Oncology, vol. 26, No. 4, Suppl. 12, Aug. 1999, No. 60-70.Applicant
• Soepenberg et al., “Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices,” Journal of Chromatography B, vol. 799, 2004, pp. 15-22.Applicant
• Soepenberg et al., “Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors,” Clinical Cancer Research, vol. 11, Jan. 15, 2005, pp. 703-711.Applicant
• Takegawa et al., “DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance,” International Journey of Cancer, vol. 141, 2017, pp. 1682-1689.Applicant
• Takiguchi et al., “Antitumor Effect of DX-8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT-11-resistant Variants Cultured in vitro and Xenografted in Nude Mice,” Jpn. J. Cancer Res., vol. 88, Aug. 1997, pp. 760-769.Applicant
• Abstract of: Tamura et al., “Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation,” Annals of Oncology, vol. 27, Supplement 6, 2016, pp. vi552-vi587.Applicant
• Tan et al., “Antibody-drug conjugates with modified linker-payloads overcome resistance to a trastuzumab-maytansinoid conjugate in multiple cultured tumor cell models,” Cancer Research, vol. 74, No. 19, Oct. 2014, Supplement Abstract 1830.Applicant
• Vogel et al., “Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer,” Journal of Clinical Oncology, vol. 20, No. 3, Feb. 1, 2002, pp. 719-726.Applicant
• Wente et al., “DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors,” Investigational New Drugs, vol. 23, 2005, pp. 339-347.Applicant
• Yano et al., “Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer,” Oncology Reports, vol. 15, 2006, pp. 65-71.Applicant
• Extended European Search Report dated May 12, 2020 for corresponding European Patent Application No. 17858462.9.Applicant
• Niikura et al: “Loss of Human Epidermal Growth Factor Receptor 2(HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors”, Journal of Clinical Oncology, vol. 30, No. 6, Feb. 20, 2012 (Feb. 20, 2012), pp. 593-599.Applicant
• Ogitani et al., “Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity,” Cancer Science, vol. 107, 2016, pp. 1039-1046.Applicant
• Tamura et al, Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation, Annals of Oncology, vol. 27, Supplement 6, 2016, pp. vi552-vi587.Applicant
• Acchione et al, Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates, mAbs, 2012, pp. 362-372.Applicant
• Colombian Reconsideration Petition dated Mar. 15, 2018 in corresponding application No. NC2016/0000187.Applicant
• Rowinsky, Preclinical and Clinical Development of Exatecan(DX-8951f), Camptothecins in Cancer Therapy, 2005, pp. 317-318.Applicant